Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice
- 3 December 2008
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 300 (21), 2542-2544
- https://doi.org/10.1001/jama.2008.754
Abstract
New testing technologies—increasingly based on genomic information—are essential in the shift toward personalized medicine and molecular targeted therapies. Considering the rapid proliferation of new tests, health care insurers and policy makers are interested in assessing evidence about their use and value. It is critical to build an evidence base to support effective decision making related to testing technologies as they are used in clinical practice. The example of human epidermal growth factor receptor 2 (HER2, or ERBB2) testing for breast cancer illustrates the challenges and opportunities. Many groups, including the Institute of Medicine, Agency for Healthcare Research and Quality, Secretary's Advisory Committee on Genetics, Health, and Society, President's Council of Advisors on Science and Technology, and Evaluation of Genomic Applications in Practice and Prevention Project, have cited the need to improve the evidence base for genomic and testing technologies. This Commentary extends previous work, emphasizing the need for evidence to assess how technologies are actually used in clinical practice.This publication has 7 references indexed in Scilit:
- The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?Genetics in Medicine, 2007
- Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2007
- A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast CancerJournal of Clinical Oncology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Insurers And ‘Targeted Biologics' For Cancer: A Conversation With Lee N. NewcomerHealth Affairs, 2007
- Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patientsInternational Journal for Quality in Health Care, 2004
- HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness AnalysisJournal of Clinical Oncology, 2004